Viral infections:

Indications for: VEKLURY

COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing who are: hospitalized, or not hospitalized and have mild to moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.

Adults and Children:

<28 days of age or <3kg: not established. Give by IV infusion over 30–120mins. ≥28 days of age (3–<40kg): Initially 5mg/kg on Day 1, followed by 2.5mg/kg once daily Day 2; (≥40kg): Initially 200mg once on Day 1, followed by 100mg once daily from Day 2. Hospitalized patients not requiring invasive mechanical ventilation and/or ECMO: treat for 5 days; if no improvement, may extend for a total duration of 10 days. Hospitalized patients requiring invasive mechanical ventilation and/or ECMO: treat for 10 days. Nonhospitalized patients: treat for 3 days.

VEKLURY Warnings/Precautions:

Should only be administered in a hospital or in a healthcare setting providing acute care. Obtain eGFR, LFTs, and prothrombin time prior to and during treatment. Consider discontinuing if ALT levels increase to >10×ULN. Discontinue if ALT elevation is accompanied by signs/symptoms of liver inflammation. Monitor for hypersensitivity reactions during and for at least 1hr after infusion; discontinue immediately if significant reactions occur. Renal impairment (eGFR <30mL/min): not recommended. Hepatic impairment. Elderly (monitor). Pregnancy. Nursing mothers.

VEKLURY Classification:

SARS-CoV-2 nucleotide analogue RNA polymerase inhibitor.

VEKLURY Interactions:

Do not administer the diluted solution simultaneously with any other medication. Concomitant chloroquine phosphate or hydroxychloroquine sulfate: not recommended.

Adverse Reactions:

Nausea, increased ALT/AST; hypersensitivity reactions, generalized seizure, rash.

Generic Drug Availability:


How Supplied:

Single-dose vial—1